How Early Cancer Detection Could Reshape Primary Care

An annual blood test for early cancer detection is being deemed as “Feasible at Scale” by experts, but what could this mean for GP practices and primary care demand? 

CREDIT: This is an edited version of an article that originally appeared in Hereford Times 

A large-scale NHS trial exploring a blood test designed to detect multiple cancers before symptoms appear suggests that annual screening of this kind could be feasible at scale within the health service, according to experts. 

The NHS-Galleri trial is evaluating how the Galleri blood test could sit alongside existing NHS screening programmes to identify cancers earlier, potentially before patients present with symptoms in general practice. While the study has not yet demonstrated a statistically significant reduction in late-stage cancer diagnoses – its primary endpoint – researchers say the emerging data still points to meaningful shifts in how cancers are detected and managed. 

How the Test Works  

The Galleri test analyses fragments of DNA in the bloodstream known as circulating tumour DNA, which may indicate the presence of cancer at an earlier stage than traditional symptom-led pathways. The trial involves more than 142,000 UK participants aged 50–77 with no cancer symptoms, with annual blood sampling over three years. Around half of participants had their samples analysed using the Galleri test. 

For GP practices, the test’s relevance lies not in the test itself being delivered in primary care, but in its potential impact on patient pathways – particularly earlier identification of cancers that currently present via vague symptoms or emergency routes. 

Early Findings 

Although the trial did not meet its primary endpoint, analysis presented at the American Society of Clinical Oncology (ASCO) suggests changes in how and when cancers are being detected. 

Across 12 pre-specified cancer types (which account for around two-thirds of cancer deaths in England), the study found: 

• Fewer late-stage (stage 4) cancer diagnoses overall  

• More cancers detected at earlier stages (stages 1–3)  

• A higher proportion of cancers identified through screening rather than symptom-led presentation  

• A reduction in emergency diagnoses, which are often more resource-intensive and urgent for GP follow-up and coordination  

Researchers also reported that in later screening rounds, reductions in advanced cancers became more pronounced, suggesting a potential cumulative effect over time. 

What GP Ppractice Mmanagers Sshould Bbe Aaware Oof 

While the test is not currently part of routine NHS screening, practice managers may want to consider the downstream operational implications if technologies like this are adopted more widely: 

• Referral patterns may change, with more cancers identified outside traditional symptomatic presentation routes  

• Earlier-stage detection could increase follow-up activity, including monitoring, imaging and secondary care coordination  

• Administrative workload may shift, particularly around patient communication and result management  

• Pathway redesign may be required, as multi-cancer screening tools evolve alongside existing NHS screening programmes  

Even without immediate implementation, the direction of travel aligns with the NHS 10-year plan focus on earlier diagnosis and more preventative care models. 

Government Position and Next Steps 

The Department of Health and Social Care has said the findings represent important evidence in the development of multi-cancer early detection (MCED) tests. Further analysis from the NHS-Galleri trial is still ongoing, and final conclusions are expected once the full dataset has been assessed. The independent UK National Screening Committee will review the evidence alongside other emerging cancer blood test technologies before making any recommendations on wider rollout. 

For GP practices, the key takeaway at this stage is not operational change, but strategic awareness: early cancer detection technologies are progressing rapidly, and any future adoption would likely have significant implications for primary care demand, patient flow and diagnostic pathways.